Pharmaceutical intermediates

Delafloxacin meglumine Intermediates

1 pharmaceutical intermediate for Delafloxacin meglumine. Indication: Community-acquired pneumonia; Bacterial skin diseases; Skin and skin structure infections.

Submit a Project All intermediates

About Delafloxacin meglumine

Originator: Wakunaga Pharmaceutical Co., Ltd.
Indication: Community-acquired pneumonia; Bacterial skin diseases; Skin and skin structure infections
Approved Date: 06/19/2017
NCE Patent: 06/19/2027
DS/DP: 10/07/2025

Available intermediates

1 intermediate currently listed for Delafloxacin meglumine. Request specifications, documentation or a quotation for any item below.

Delafloxacin meglumine intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
3,5-Difluoropyridine-2,6-diamine	247069-27-8	/	/

Other programs under D

Dabigatran Etexilate Dabigatran etexilate mesylate Dabrafenib Mesylate Dacomitinib Danicopan Dapagliflozin Daridorexant Hydrochloride Darolutamide

Building toward Delafloxacin meglumine?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here